Dr. Shomik Maruf [SHMF]

Full Publication list:

Google Scholar: https://scholar.google.com/citations?user=f95G6woAAAAJ&hl=en&oi=ao

Orcid ID: 0000-0001-8463-5326

As First/Co-first Author:

1.       Maruf S, Uddin R, Luba FR, Sagar SK, Ghosh D, et al. (2026) Mapping the last mile: Micro-stratification for sustained visceral leishmaniasis elimination in Bangladesh. PLOS Neglected Tropical Diseases 20(5): e0013504. [Link]

2.       Maruf S, Sagar SK, Rashid MU, Uddin MR, Ghosh D, Ghosh P, Nath R, Sohel AN, Aktaruzzaman MM, Islam N, Banjara MR. Assessment of treatment outcomes of visceral leishmaniasis (VL) treated cases and impact of COVID-19 on VL Management and Control Services in Bangladesh. Journal of Infection and Public Health. 2023 Sep 9. [Link]

3.       Maruf S, Sagar SK, et al. Revisiting the diagnosis and treatment of Para Kala-azar Dermal Leishmaniasis in the endemic foci of Bangladesh. PloS one. 2023 Jan 20;18(1):e0280747 [Link]

4.       Ghosh P, Chowdhury R, Maruf S, Picado A, Hossain F, Owen SI, Nath R, Baker J, Hasnain MG, Shomik MS, Ghosh D. Gauging the skin resident Leishmania parasites through a loop mediated isothermal amplification (LAMP) assay in post-kala-azar dermal leishmaniasis. Scientific Reports. 2022 Oct 27;12(1):18069. [Link]

5.       Maruf S, et al. Corneal complications following Post Kala-azar Dermal Leishmaniasis treatment. PLoS neglected tropical diseases. 2018 Sep 17;12(9):e0006781 [Link]

6.       Maruf S, et. al. AmBisome Induced Avascular Necrosis of the Alae of the Nose of a very young girl suffering from Kala-azar–a Case Report. Pharmacology research & perspectives. 2016 Dec 1;4(6) [Link]

7.       Hasnain MG, Maruf S, et al. Managing Severe Tetanus without Ventilation Support in a Resource-limited Setting in Bangladesh. The American journal of tropical medicine and hygiene. 2018 Sep 10 [Link]

As Co-author:

1.       Hossain F, Sharfaraz A, Ghosh P, Sarwar G, Uddin MR, Rashid MU, Ghosh D, Nath R, Maruf S, Sagar SK, Shomik MS. Visceral Leishmaniasis & HIV Co-infection in Bangladesh: Investigating Prevalence and Policy Recommendations. Journal of Infection and Public Health. 2026 Apr 27:103233. [Link]

2.       Luba FR, Ghosh P, Anwar S, Dey BP, Bhowmick B, Arafat SM, Saleh AA, Shomik MS, Maruf S, Sagar SK, Ashaduzzaman M. Cervical lymph node TB: diagnostic yield and patient profile. IJTLD open. 2026 Feb 1;3(2):57-64. [Link]

3.       Sagar SK, Maruf S, Chowdhury R, Rashid MM, Aktaruzzaman MM, et al. Investigating the optimum timeline for final cure assessment of treated Visceral Leishmaniasis patients in Bangladesh. PLOS Global Public Health. 2026 Feb 26;6(2):e0006002. [Link]

4.       Chu WY, Singh OP, Sundar S, Pandey K, …., Maruf S, et al. Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis. International Journal of Antimicrobial Agents. 2026 Jan 9:107713. [Link]

5.       Hossain F, Ghosh P, Chowdhury FR, Basher A, …., Maruf S, et al. Evaluating a rapid molecular assay in a mobile laboratory for improved diagnosis of dengue in Bangladesh. International Journal of Infectious Diseases. 2025 Jan 1;150:107299. [Link]

6.       Ghosh D, Sagar SK, Uddin MR, Rashid MU, Maruf S, Nath R, et al. Post kala-azar dermal leishmaniasis burden at the village level in selected high visceral leishmaniasis endemic upazilas in Bangladesh. International Journal of Infectious Diseases. 2024 Oct 1;147:107213. [Link]

7.       Sundar S, Pandey K, Mondal D, Madhukar M, …., Maruf S, et al. A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh. PLOS Neglected Tropical Diseases. 2024 Jun 20;18(6):e0012242. [Link]

8.       Ghosh D, Rashid MU, Sagar SK, Uddin MR, Maruf S, et al. Epidemiological, serological, and entomological aspects of visceral leishmaniasis (VL) in suspected new VL foci in Bangladesh. Acta Tropica. 2023 Dec 1;248:107021. [Link]

9.       Ghosh P, Chowdhury R, …., Maruf S, et al. Evaluation of a Point-of-Need Molecular Diagnostic Tool Coupled with Rapid DNA Extraction Methods for Visceral Leishmaniasis. Diagnostics. 2023 Dec 11;13(24):3639. [Link]

10.   Hossain F, Picado A, …., Maruf S, et al. Evaluation of Loopamp™ Leishmania Detection Kit and Leishmania antigen ELISA for post- elimination detection and management of visceral leishmaniasis in Bangladesh. Frontiers in Cellular and Infection Microbiology. 2021;11 [Link]

11.   Ghosh P, Sharma A, ...., Maruf S, et al. A Multi-Country, Single-Blinded, Phase 2 Study to Evaluate a Point-of-Need System for Rapid Detection of Leishmaniasis and Its Implementation in Endemic Settings. Microorganisms. 2021 Mar;9(3):588 [Link]

12.   Chowdhury R, Ghosh P, …., Maruf S, et al. Evaluation of rapid extraction methods coupled with a recombinase polymerase amplification assay for point-of-need diagnosis of post-kala-azar dermal leishmaniasis. Tropical Medicine and Infectious Disease. 2020 Jun;5(2):95 [Link]

13.   Khan MA, Chowdhury R, Nath R, Hansen S, Nath P, Maruf S, et al. Imported cutaneous leishmaniasis: molecular investigation unveils Leishmania major in Bangladesh. Parasites & vectors. 2019 Dec 1;12(1):527 [Link]

14.   Hasnain MG, Nath P, Maruf S, et al. Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study. BMC research notes. 2018 Dec;11(1):918 [Link]

15.   Ghosh P, Hasnain MG, ….., Maruf S, et al. Evaluation of real-time PCR for diagnosis of Post-kala-azar dermal leishmaniasis (PKDL) in an endemic foci of Bangladesh. InOpen Forum Infectious Diseases 2018 Sep 15 [Link]

16.   Hossain MS, Kumar A, …., Maruf S, et al. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh’s National Kala-azar Elimination Programme. Infectious diseases of poverty. 2018 Dec;7(1):80 [Link]

17.   Chowdhury FR, Rahman MM, Maruf S, et al. Salbutamol in acute organophosphorus insecticide poisoning – a pilotdose-response phase II study. Clinical Toxicology. 2018 Feb 20:1-8 [Link]

18.   Basher A, Maruf S, et al. Case report: treatment of widespread nodular post kala-azar dermal leishmaniasis with extended-dose liposomal amphotericin B in Bangladesh: a series of four cases. The American journal of tropical medicine and hygiene. 2017 Oct 11;97(4):1111-5 [Link]

1. Study UK Alumni Awards, Bangladesh, 2026 – British Council, UK
2. Chevening Scholarship 2019/20 – FCDO, UK.
3. 100 Students Grant Award – 6^th World Leishmania Congress, 2017, Toledo, Spain.
4. Young Researcher Grant Award – 10^th ECTMIH, 2017, in Antwerp, Belgium.

1.       MSc in Medical Parasitology

London School of Hygiene & Tropical Medicine (LSHTM), UK 

Thesis: Role of Atypical Water Storage as a Potential Site for Outdoor Larval Development for Major Arboviral Vector (Aedes sp.) at a Neighborhood Scale

2.       Master of Public Health (Epidemiology)

North South University, Bangladesh 

Thesis: Effect of Magnesium Sulphate in Managing Severe Tetanus Patients without Ventilation Support in Resource-Limited Settings in Bangladesh

3.       Bachelor of Medicine and Bachelor of Surgery (MBBS)

Sylhet MAG Osmani Medical College, Bangladesh 

Lecturer

Department of Public Health, North South University, Dhaka, Bangladesh

Tenures:

• June 2026 – Present (Full Time) 
• May 2022 – May 2026 (Part time)

PBH 101: Introduction to Public Health

PBH 101 L: Introduction to Public Health (Lab)

PBH 105: Anatomy and Physiology 

• Bangladesh Medical and Dental Council (BMDC)
• Technical Working Group for Visceral Leishmaniasis, Kala-azar Elimination Programme, Bangladesh.
• American Society of Tropical Medicine

Research Interest:

• Infectious Disease,
• Neglected Tropical Diseases,
• Implementation Research, 
• Epidemiology,
• Clinical and Diagnostic Trials,
• Health Systems Research,
• Health Economic Evaluation and
• Public Health Programme Evaluation.

As Principal Investigator

1.       Evaluating the effectiveness of a virtual reality-based training platform in improving the quality of stroke-care in a resource-limited setting – The University of Newcastle, NSW, Australia. [Funding amount – US$ 13,939]

2.       An Open label, Randomized Non-Inferiority Trial Comparing Safety and Immunogenicity of Intradermal versus Intramuscular Administration of Registered Rabies Vaccine in Healthy Bangladeshi Adults – Popular Pharmaceuticals PLC. [Funding amount – US$ 93,629]

3.       Determining the Rate & Duration of Infectivity Treated Post Kala-azar Dermal Leishmaniasis (PKDL) Patients in the Transmission of Leishmania donovani (LD) Infection to Sand Fly – CDC, DGHS, Government of Bangladesh [Funding amount: US$ 9,213]

4.       Determining the factors associated with VL Relapse in Bangladesh – CDC, DGHS, Government of Bangladesh [Funding amount: US$ 9,710]

5.       Micro stratification of Visceral Leishmaniasis (VL) Endemic Areas to Identify Hotspots and Disease Shifting Pattern in Bangladesh – TDR WHO [Funding amount: US$ 19,999]

6.       Ensuring Health Equity and Economic Participation for Chronic Lymphatic Filariasis Patients through Surgical Intervention in Bangladesh – Bangladesh Bank [Funding amount: US$ 37,695]

7.       Follow up Assessment of Visceral Leishmaniasis (VL) Treated Patients and Assessment of Impact of COVID-19 in VL Control Services in Bangladesh – TDR WHO [Funding amount: US$ 45,000]

8.       Repurposing Ivermectin (IVM) for Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL): Safety and response to Multiple doses of Ivermectin – CDC, DGHS, Government of Bangladesh* [Funding amount: US$ 11,820]

9.       Determining Vector Density through Sticky Trap in the VL Endemic Foci in Bangladesh – CDC, DGHS, Government of Bangladesh. [Funding amount: US$ 11,820]

As Co-Principal Investigator

1.       Assessing Safety and Efficacy of repurposed oral Ivermectin in PKDL Treatment – Cures Within Reach - [Funding amount: US$ 49,962]

2.       Developing a sustainable model for the periodic surveillance at the post elimination phase of Lymphatic Filariasis – CDC (USA) [Funding amount: US$ 750,000]

3.       Evaluation of diagnostics for visceral leishmaniasis vis-à-vis embedding of the diagnostics into the secondary health care system in Bangladesh – TDR WHO [Funding amount: US$ 50,000]

As Co-Investigator

1.       Determination of Prevalence of Post Kala-azar Dermal Leishmaniasis (PKDL) and Assessment of Treatment Seeking Behavior of PKDL Patients in Bangladesh – TDR WHO [Funding amount: US$ 55,000]

2.       Epidemiological, Serological and Entomological Investigation of New Visceral Leishmaniasis (VL) Foci in Bangladesh – TDR WHO [Funding amount: US$ 50,000]

3.       A multi-country, single-blinded, phase 2 study to evaluate a point-of-need system for rapid detection of leishmaniasis and its implementation in endemic settings – PATH ^# [Funding amount: US$ 44,821]

4.       A study for exploring the Visceral Leishmaniasis and Post-Kala-azar Dermal Leishmaniasis (PKDL) in transmission of Leishmania donovani (LD) infection to sand fly – DNDi [Funding amount: US$ 142,862]

5.       An Open label, Randomized, Clinical Trial of Two Regimens to Assess the Safety and Efficacy for Treatment of PKDL Patients in the Indian subcontinent  – DNDi * [Funding amount: US$ 179,988.78]

6.       A Multi-Center, Open-Label, Randomized, Two treatment, Parallel, Single period, Multiple-Dose, Steady state, Global Bioequivalence study of Amphotericin B Liposome (Auromedics Pharma LLC, USA) in Visceral Leishmaniasis patients under fed condition. – Axis Pharmaceuticals* (for US FDA approval of the drug) [Funding amount: US$ 275,892]

As Project Co-Lead

1.       Support Increased Coverage of Morbidity and Disability Prevention for Lymphatic Filariasis (LF) in Bangladesh – FCDO [Funding amount: £ 1,942,564]